Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Consensus Price Target from Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $15.40.

Several research firms have recently weighed in on ANRO. William Blair reissued an "outperform" rating on shares of Alto Neuroscience in a report on Friday, March 21st. HC Wainwright initiated coverage on shares of Alto Neuroscience in a research report on Monday, April 7th. They issued a "buy" rating and a $10.00 price objective for the company.

Alto Neuroscience Stock Performance

Shares of ANRO stock traded up $0.02 on Friday, reaching $2.36. The stock had a trading volume of 7,066 shares, compared to its average volume of 380,891. The firm has a market capitalization of $63.75 million, a price-to-earnings ratio of -0.93 and a beta of 1.87. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $17.55. The firm's 50-day moving average is $2.47 and its two-hundred day moving average is $3.47.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.09. On average, research analysts expect that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANRO. Wells Fargo & Company MN increased its stake in shares of Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock worth $46,000 after purchasing an additional 3,139 shares during the period. Deutsche Bank AG increased its holdings in Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock worth $64,000 after purchasing an additional 3,629 shares in the last quarter. Invesco Ltd. purchased a new stake in shares of Alto Neuroscience during the first quarter worth $67,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Alto Neuroscience in the fourth quarter worth $74,000. Finally, Jane Street Group LLC grew its stake in shares of Alto Neuroscience by 72.0% during the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock valued at $79,000 after buying an additional 7,783 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.